A roadmap for the development and validation of event-related potential biomarkers in schizophrenia research.
A roadmap for the development and validation of event-related potential biomarkers in schizophrenia research.
复制标题
DOI：
10.1016/j.biopsych.2010.09.021
复制
发表时间：
2011-07-01
影响因子：
10.6
通讯作者：
Uhlhaas, Peter J.
中科院分区：
文献类型：
--
作者：
Luck, Steven J.;Mathalon, Daniel H.;O'Donnell, Brian F.;Hamalainen, Matti S.;Spencer, Kevin M.;Javitt, Daniel C.;Uhlhaas, Peter J.
开发精神疾病认知功能障碍治疗方法的新努力将极大地受益于生物标志物，这些生物标志物提供了对认知基础神经事件的敏感和可靠的测量。在这里，我们评估的承诺，事件相关电位（ERPs）作为生物标志物的认知功能障碍的精神分裂症。我们的结论是，ERP有几个理想的属性：（a）他们提供了一个直接测量的电活动在神经传递过程中;（B）他们的高时间分辨率使得它可以测量神经同步性和振荡;（c）他们是相对便宜和方便的记录;（d）动物模型是容易获得的几个ERP组件;（e）几十年的研究已经确立了ERP测量在精神疾病中的敏感性和可靠性;（f）已经证明了对关键测量进行大规模N（>500）多地点研究的可行性。因此，ERPs可能有助于识别内在表型和确定治疗靶点，用于评估动物和人类的新化合物，以及用于识别早期干预或特定治疗的良好候选人。然而，在ERPs作为生物标志物广泛应用于精神分裂症研究之前，必须克服一些挑战，我们对开发和验证基于ERPs的生物标志物的研究提出了一些建议，这些生物标志物可以对治疗开发产生真实的影响。
New efforts to develop treatments for cognitive dysfunction in mental illnesses would benefit enormously from biomarkers that provide sensitive and reliable measures of the neural events underlying cognition. Here we evaluate the promise of event-related potentials (ERPs) as biomarkers of cognitive dysfunction in schizophrenia. We conclude that ERPs have several desirable properties: (a) they provide a direct measure of electrical activity during neurotransmission; (b) their high temporal resolutions makes it possible to measure neural synchrony and oscillations; (c) they are relatively inexpensive and convenient to record; (d) animal models are readily available for several ERP components; (e) decades of research has established the sensitivity and reliability of ERP measures in psychiatric illnesses; and (f) feasibility of large N (>500) multi-site studies has been demonstrated for key measures. Consequently, ERPs may be useful for identifying endophenotypes and defining treatment targets, for evaluating new compounds in animals and in humans, and for identifying individuals who are good candidates for early interventions or for specific treatments. However, several challenges must be overcome before ERPs gain widespread use as biomarkers in schizophrenia research, and we make several recommendations for the research that is necessary to develop and validate ERP-based biomarkers that can have a real impact on treatment development.
登录
查看更多内容
影响因子：
6.6
作者：
Ford, Judith M.;Krystal, John H.;Mathalon, Daniel H.
通讯作者：
Mathalon, Daniel H.
影响因子：
56.9
作者：
ARTHUR, DL;STARR, A
通讯作者：
STARR, A
影响因子：
6.6
作者：
Calkins, Monica E.;Dobie, Dorcas J.;Braff, David L.
通讯作者：
Braff, David L.
影响因子：
2.7
作者：
Law, Samuel K.
通讯作者：
Law, Samuel K.
影响因子：
3.7
作者：
Kappenman ES;Luck SJ
通讯作者：
Luck SJ